🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Omeros looks forward to presenting preclinical data for OMS906, our MASP-3 inhibitor for #PNH and other alternative pathway disorders, at the European Meeting on Complement in Human Disease in Bern, Switzerland from 8:00-8:15 am CEST on August 28, 2022.

Let’s Light The Night! Omeros has partnered with The Leukemia & Lymphoma Society to bring “light to the darkness of cancer”. Join us 10/22 in Seattle as we raise our lanterns to celebrate survivors, honor those we’ve lost, and all who continue to fight. Visit lightthenight.org/home for more details.

At Omeros, cutting-edge science serves as a foundation for a deep and diverse pipeline. As #KidneyWk 2022 starts, we will present data for narsoplimab, our novel MASP-2 antibody: “Narsoplimab Treatment for Recurrent IgAN Stabilized eGFR and Proteinuria” rb.gy/mwyndi

Interested in the role of MASP-2 and the lectin pathway in complement-related hematologic disease? Omeros’ #narsoplimab will be featured in two presentations this weekend (Apr 23) at EBMT in Paris. Learn more here: bit.ly/3N3nnbe. #omeros #EBMT #TA-#TMA #HSCT-#TMA

Omeros Corporation reports interim data with alternative pathway inhibitor OMS906 as monotherapy in patients with Paroxysmal Nocturnal Hemoglobinuria bit.ly/3AtoEk9

Omeros Corporation’s pre-specified interim analysis of the Phase 1b clinical trial of OMS906, our MASP-3 inhibitor in paroxysmal nocturnal hemoglobinuria, was identified as a top 5 late-breaking submission for #EHA2023 bit.ly/3NhWLDb – presentation this Sunday, June 11

Omeros Announces Online Publication Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with TA-TMA. A poster presentation will be made at ASH 2023, Dec. 9-12 in San Diego. The abstract (3543) is available at hematology.org

#Omeros announces that 2 abstracts (573 & 4082) directed to #OMS906—an investigational MASP-3 inhibitor—will be presented at #ASH December 10-11, 2023 in San Diego. Both are now available on the ASH website at hematology.org More information here: tinyurl.com/2y2e9k8r

Join Omeros at #Tandem24 on February 22, from 6:45 PM-7:45 PM, for a presentation of Poster 186: Real-World Experience with Narsoplimab (OMS721) for the Treatment of Transplant-Associated Thrombotic Microangiopathy #TA-#TMA shorturl.at/hvwJ6

OMEROS, in recognition of #PNHAwarenessWeek, wants to highlight the importance of supporting the PNH community with resources and education. Learn more: aamds.org/what-you-can-d…

In support of #PNHAwarenessWeek, OMEROS is continuing to listen to patients about their journeys. We’re proud of the progress we’re making to target and treat the ongoing unmet needs of patients living with PNH.

Omeros' zaltenibart (OMS906), the first-in-class MASP-3 inhibitor, has received FDA rare pediatric disease designation for #C3G, a devastating kidney disorder affecting children and young adults with no approved treatments. C3G can lead to end-stage renal disease within a decade.

Omeros provides update on progress toward BLA resubmission. More info: investor.omeros.com/news-releases/… #TA-#TMA #transplant #complementinhibitor

#OMEROS announces upcoming presentations at #ASH24, highlighting progress in late-stage development of lead MASP-3 inhibitor #zaltenibart in #PNH. More info: investor.omeros.com/news-releases/…

Attending #ASH24? Come visit #OMEROS at booth 321 to learn about #zaltenibart, our lead investigational MASP-3 inhibitor for #PNH.

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with #TA-#TMA. Narsoplimab BLA will be resubmitted to FDA as soon as possible. #ComplementInhibition

Omeros announces newly completed sensitivity analyses demonstrating robustness of previously announced survival superiority over external control in #TA-#TMA More info: shorturl.at/Ft34g #narsoplimab #complementinhibitor #omeros

Omeros Corporation announced two presentations that will be featured at the 2025 Tandem Meetings – February 12-15, 2025 in Honolulu, HI. Both presentations report real world outcomes from patients with TA-TMA treated with narsoplimab supplied by Omeros under an expanded access

Omeros announces robust improvement in survival for #narsoplimab expanded access program in #TA-TMA over external control. More info: shorturl.at/NA9fy #complementinhibitor #omeros